Mankind Pharma faces Rs 183 crore tax demand, plans to appeal

Mankind Pharma has received tax demand orders from the Income Tax Department for Assessment Years (AY) 2014-15 to 2017-18, amounting to ₹183.11 crore, including interest. The demand arises from the disallowance of various expenditures under Section 37(1) of the Income-tax Act, 1961.

According to a regulatory filing, the orders were issued by the Office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi.

The orders for AY 2014-15 and 2016-17 were dated March 24, 2025, while those for AY 2015-16 and 2017-18 were dated March 25, 2025. The company received the orders through the IT portal on March 28, 2025.

Mankind Pharma has said that it believes the tax demand is not legally justified and that it has strong factual and legal grounds to challenge the order. The company also asserted that the order is not expected to have any material impact on its financials or operations.

The pharmaceutical firm plans to appeal the order under applicable laws. Investors will be monitoring the situation closely as the company navigates this tax challenge.

Related Posts

  • Pharma
  • April 3, 2025
  • 101 views
Nifty Pharma soars 3% on exclusion from Trump’s reciprocal tariffs; Sun Pharma, IPCA Labs up 5%

Domestic pharmaceutical players heaved a sigh of relief in trade on April 3, while the other sectors see intense selling pressure, as the White House has excluded pharmaceuticals products from…

  • Pharma
  • April 3, 2025
  • 121 views
Pharma tariff exemption: Temporary relief, but higher tariffs may be imposed later, warns analyst

US President Donald Trump has exempted pharmaceuticals from his reciprocal tariff plan announced on April 3. While he imposed a 26% tariff on other imports from India, this exemption has…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Is Gujarat’s Health Department Rebelling against PM Modi Government?

Is Gujarat’s Health Department Rebelling against PM Modi Government?

Nifty Pharma soars 3% on exclusion from Trump’s reciprocal tariffs; Sun Pharma, IPCA Labs up 5%

Nifty Pharma soars 3% on exclusion from Trump’s reciprocal tariffs; Sun Pharma, IPCA Labs up 5%

Pharma tariff exemption: Temporary relief, but higher tariffs may be imposed later, warns analyst

Pharma tariff exemption: Temporary relief, but higher tariffs may be imposed later, warns analyst

Fake pharmacy registration racket busted in Delhi, 47 held

Fake pharmacy registration racket busted in Delhi, 47 held